Pharmacology recall alongside GPhC assessment study
Use generic names and source-linked mechanism summaries for a focused review session within your UK study plan.
A practical study routine
Start with a class or body system, and keep the generic name as your anchor. Read the mechanism, close the card and explain it in your own words. Check UK product information in your usual references before carrying over any brand or indication from a US card.
Alternate a short class quiz with a mechanism quiz. Write down uncertain distinctions to discuss with your tutor or supervisor. Give calculations and applied practice their own time in the wider schedule; a recognition quiz cannot substitute for those tasks.
The 2026 Common Registration Assessment framework sets the official scope. These exercises use US drug-card content and do not teach UK law, reproduce assessment questions or provide an assessment-readiness score.
Capsera is an independent study aid. These are original exercises, not official exam questions or a complete exam course.
Plan your review days
One mechanism summary for each reviewed name ending
-pril · Lisinopril: Inhibits angiotensin-converting enzyme, blocking conversion of angiotensin I to angiotensin II and suppressing the renin-angiotensin-aldosterone system.
-sartan · Losartan: Losartan and its active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II at its receptor.
-olol · Metoprolol: Beta-1 selective (cardioselective) adrenergic receptor blocker without intrinsic sympathomimetic activity; blocks beta-2 at higher levels.
-statin · Atorvastatin: Selectively and competitively inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. In animal models, increased hepatic LDL receptors also contribute to LDL uptake and breakdown.
-prazole · Omeprazole: Substituted benzimidazole that inhibits the H+/K+ ATPase (proton pump) of the gastric parietal cell, blocking the final step of acid secretion.
-gliflozin · Empagliflozin: Inhibits renal SGLT2, reducing glucose reabsorption and increasing urinary glucose excretion; also reduces sodium reabsorption and increases sodium delivery to the distal tubule.
-gliptin · Sitagliptin: A DPP-4 inhibitor believed to act by slowing incretin inactivation. It increases and prolongs active GLP-1 and GIP levels, which influence insulin and glucagon in a glucose-dependent manner.
-glutide · Semaglutide: GLP-1 analogue that selectively binds and activates the GLP-1 receptor; albumin binding gives it a long half-life.
-triptan · Sumatriptan: Presumed to act in migraine through 5-HT1B/1D agonism on intracranial vessels and trigeminal sensory nerves, producing cranial vasoconstriction and reduced pro-inflammatory neuropeptide release.
-xaban · Apixaban: Selective inhibitor of free and clot-bound factor Xa and prothrombinase, independent of antithrombin III; decreases thrombin generation.
Capsera